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Reverse cholesterol transport (RCT) refers to the mobilization of cholesterol on HDL particles (HDL-C) from
extravascular tissues to plasma, ultimately for fecal excretion. Little is known about how HDL-C leaves peripheral tissues to reach plasma. We first used 2 models of disrupted lymphatic drainage from skin — 1 surgical and
the other genetic — to quantitatively track RCT following injection of [3H]-cholesterol–loaded macrophages
upstream of blocked or absent lymphatic vessels. Macrophage RCT was markedly impaired in both models,
even at sites with a leaky vasculature. Inhibited RCT was downstream of cholesterol efflux from macrophages,
since macrophage efflux of a fluorescent cholesterol analog (BODIPY-cholesterol) was not altered by impaired
lymphatic drainage. We next addressed whether RCT was mediated by lymphatic vessels from the aortic wall
by loading the aortae of donor atherosclerotic Apoe-deficient mice with [2H]6-labeled cholesterol and surgically
transplanting these aortae into recipient Apoe-deficient mice that were treated with anti-VEGFR3 antibody to
block lymphatic regrowth or with control antibody to allow such regrowth. [2H]-Cholesterol was retained in
aortae of anti–VEGFR3-treated mice. Thus, the lymphatic vessel route is critical for RCT from multiple tissues,
including the aortic wall. These results suggest that supporting lymphatic transport function may facilitate
cholesterol clearance in therapies aimed at reversing atherosclerosis.
Introduction
Atherosclerosis is a major cause of morbidity and mortality in
the world. At the cellular level, atherosclerotic plaques are characterized by macrophages loaded with cholesterol esters. Indeed,
ongoing recruitment of monocyte-derived macrophages into
plaque is a key event in disease progression. Removal of macrophages involves a cessation of recruitment that correlates with the
mobilization of cholesterol stored within macrophages as cholesterol esters (1). Cholesterol ester–loaded macrophages are not
inherently proinflammatory (2). Thus, it is not yet understood
how cholesterol drives monocyte recruitment to sustain plaque
progression. Deposition of cholesterol crystals (3) or undesirable
immunity to cholesterol-associated apoproteins (4) are possible
means by which inflammation can be sustained in an environment rich in macrophages and cholesterol. Regardless of our
gaps in understanding the links between cholesterol in the artery
wall and inflammation that drives disease progression, it seems
clear that removal of cholesterol, which is largely stored in macrophages as cholesterol esters, from the aortic wall would comprise
a step toward disease reversal, as observed in primate models of
atherosclerosis regression (5).
Removal of cholesterol from macrophages requires hydrolysis,
mobilization, and efflux of stored cholesterol ester from macrophages to lipoprotein acceptors, especially apoA-I, by virtue of
the formation of HDL. Cholesterol solubilized by apoA-I and
phospholipids (HDL-C) moves through the bloodstream to the
liver for eventual fecal elimination (6), or through a nonbiliary
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pathway (7, 8). This entire transport process is called reverse
cholesterol transport (RCT), and macrophage RCT refers specifically to the removal of cholesterol from macrophage cholesterol
ester stores (9). The fraction of cholesterol disposed of through
macrophages is small overall compared with the amounts in the
entire body; nonetheless, as cells that are active in tissue remodeling and clearance of cellular debris, macrophages may take in
and need to dispose of more cholesterol than many other cell
types (9, 10). Although much is known about cholesterol efflux
from macrophages and subsequent uptake of cholesterol in the
liver and its secretion into bile, some steps are poorly understood. In particular, little is known about how HDL or apoA-I
enters or leaves plaques, or indeed any other tissues, to return to
the bloodstream.
The lymphatic system generally governs the transport of macromolecules from the extravascular space into the blood (11).
Accordingly, human peripheral lymph contains HDL-C (12–14),
and estimates indicate a lymph transport of more than 300 mg
per day (15). Placed into the context of estimates of overall neutral
and acidic sterol excretion per day per kilogram in humans (16),
the flux through lymph could represent a substantial pathway
for removal of cholesterol from tissues body wide. However, since
apoA-1, which drives the formation of HDL, is thought to enter
extravascular tissues by crossing the blood endothelium (17), it
is unclear whether clearance of HDL-C from tissues by traversing
vascular endothelium may also occur and diminish the need for
lymphatic transport to remove HDL-C from tissues. Thus, we set
out to address whether lymphatic vessels participate critically in
RCT from peripheral tissues, including skin and the aortic wall,
where macrophage RCT is especially relevant.
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Figure 1
Surgical separation of lymphatic vessels and its impact on RCT. (A)
Image of the mouse tail following surgical separation of lymphatic
vessels (red arrow). White boxes depict approximate location of
tail-draining lymph nodes. These nodes (lower photomicrographs)
were removed after Evans blue dye was injected into the tail; enlarged
images of the 2 lymph nodes are shown from a control mouse receiving
a sham operation (Sham) and 1 that underwent lymphatic separation
(Surgery). Similar results were obtained in 4 other analyses (n = 5)
using Evans blue dye to verify repeated success of the procedure.
(B) [3H]-Cholesterol–loaded macrophages were injected into the peritoneum (i.p.), in skin of the tail, or the lower back of WT or Apoa1
transgenic mice. Tritium counts in the plasma are charted. (C) Tritium
counts in plasma in control mice (solid line) or in those subjected to
lymphatic separation (dotted line) after [3H]-cholesterol–loaded macrophages were injected into the tail upstream (with respect to lymph flow)
of the lymphatic separation as shown in A. (D) Compiled tritium counts
in plasma, liver, and feces from the experimental design used in C. (E)
Cholesterol efflux was monitored as the loss of fluorescence from gated
CD45.1 macrophages loaded ex vivo with BODIPY-cholesterol and
retrieved 24 hours later from the tails of WT or Apoa1 transgenic mice
with or without lymphatic separation. All data represent the mean ± SEM
from at least 2 experiments performed with 5 replicates per experimental group. *P < 0.05; **P < 0.01. CPM, counts per minute.

Results
Surgical ablation of lymphatic vessels in the skin blocks RCT without
impairing cholesterol efflux from macrophages. To determine whether lymphatic vessels have a quantitatively important role in the
clearance of HDL, we first adapted an in vivo macrophage RCT
assay (6, 18, 19). In this assay, RCT is measured by injection of
[3H]-cholesterol–loaded macrophages into peripheral tissues of
mice to track the mobilization of [3H]-cholesterol to plasma, liver,
and feces (6, 18). In preparation for this assay, we surgically separated dermal lymphatic vessels to disrupt lymph flow from the
tail dermis of mice without damaging the blood circulation (20).
Intradermal injection of Evans blue dye into the tail tip, upstream
of the separation, revealed very little dye retrieved in draining lymph nodes compared with the sham control (Figure 1A).
This finding allowed us to set up a model to examine whether
RCT is intact or severely disrupted after [3H]-cholesterol–loaded
macrophages are injected into the tail upstream of the lymphatic
separation. In control mice without lymphatic separation, the
RCT response to [3H]-cholesterol–loaded macrophages injected
into the tail skin was much less robust than in the lower back
skin or the previously studied peritoneal cavity (Figure 1B and
ref. 18), importantly revealing that different body sites support
macrophage RCT to differing extents. As expected (18), macrophage RCT from the tail increased markedly in Apoa1 transgenic
mice (Figure 1B), which bear higher levels of HDL (21). Therefore, we utilized Apoa1 transgenic mice in ensuing macrophage
RCT assays in the tail following lymphatic separation versus sham
operation to improve the magnitude of our readout.
Surgical separation of tail lymphatic vessels did not alter
plasma lipoprotein profiles (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/
JCI63685DS1). [3H]-Cholesterol did not appear in plasma for
2

more than 8 hours after [3H]-cholesterol–loaded macrophage
injection, but counts peaked by 24 hours (Figure 1C). [3H]-Cholesterol levels were reduced by 50% in plasma in mice with surgically
separated lymphatic vessels (Figure 1C). When normalized to the
weight or volume of each compartment, there was a net reduction
of [3H]-cholesterol in plasma, liver, and feces (Figure 1D). Surgical
separation of lymphatic vessels in the tail reduced net RCT by 54%
at 24 hours and by 44% at 48 hours (Figure 1D). These data suggest that lymphatic vessels are important conduits for RCT.
However, it is possible that cholesterol efflux from macrophages,
rather than egress of HDL from tissue, was reduced in the skin
with lymphatic separation. To examine this possibility, we loaded
macrophages ex vivo with BODIPY-cholesterol, a fluorescent analog of cholesterol in which a BODIPY moiety is covalently linked
to C24 of the aliphatic side chain (22, 23), allowing us to monitor
cholesterol efflux from individual macrophages using flow cytometry. Like native cholesterol, we found that BODIPY-cholesterol
efflux required the expression of ABCA1/ABCG1 (Supplemental
Figure 2). Therefore, we prepared macrophages from CD45.1+ congenic C57BL/6 mice, loaded them with BODIPY-cholesterol, and
injected them into the tails of CD45.2+ WT or Apoa1 transgenic
mice with or without lymphatic vessel separation. At 24 hours,
we digested the tail tissue to retrieve injected cells and gated on
CD45.1+ cells to identify the transferred macrophages. Macrophages injected into Apoa1 transgenic mice had reduced fluorescence intensity (shift to the left), indicative of increased BODIPYcholesterol unloading, compared with injection into WT recipient
mice (Figure 1E). Most importantly, there was no difference in this
shift to the left in Apoa1 transgenic mice where lymphatic vessels
had been separated (Figure 1E), as the mean fluorescence intensity
in WT recipients was approximately 600 in WT mice and dropped
to 350 in both groups of Apoa1 transgenic mice. Thus, plasma lipoprotein profiles and cholesterol efflux from macrophages were not
significantly affected by lymphatic separation, indicating that the
substantial reduction in RCT observed after surgically blocking
lymphatic transport is attributable to a critical role of lymphatic
vessels in transporting HDL-C during RCT.
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Figure 2
RCT in Chy mutant mice. (A) [3H]-Cholesterol–loaded macrophages
were injected into the rear footpads of Chy mice or control littermates
and tritium counts were assessed in plasma at 24 hours. Two background strains were compared; injected macrophages were made from
the bone marrow of mice on the same background as the recipients
into which they were injected. (B) Compiled tritium counts in plasma
(black), liver (white), and feces (gray) from C57BL/6 Chy and WT mice
euthanized 24 hours after [3H]-cholesterol–loaded macrophages were
injected into the rear footpad. (C) Compiled tritium counts in plasma
(black), liver (white), and feces (gray) from C57BL/6 Chy and WT mice
euthanized 24 hours after [3H]-cholesterol–loaded macrophages were
injected into the scapular area of the back skin. (D) Lipoprotein profiles in the plasma of Chy mice and littermate controls from the mixed
or C57BL/6 backgrounds. Each panel represents 2 experiments performed with 5 replicates per experimental group (mean ± SEM). Statistics compared Chy mice with their control littermates in each case.
*P < 0.05; **P < 0.01; ***P < 0.001.

Genetic ablation of lymphatic vessels disrupts RCT from skin. Socalled “Chy mice” carry 1 mutant allele of the VEGF-C receptor
VEGFR3 that controls lymphatic vessel development but does
not affect blood vessels (11, 24). Experiments in these mice would
avoid the need for surgical separation of lymphatics and would
instead comprise a genetic approach to addressing the quantitative importance of lymphatic vessels in RCT. Chy mice are
reported to selectively lack lymphatic capillaries in skin (25). We
observed that the loss of lymphatic vessels was complete in the
limbs and ears of Chy mice, but that the body trunk skin retains
some lymphatic vasculature (26). This retention in the body trunk
resulted in normal immune cell trafficking through lymph, with
molecular transport that was partially reduced, but less substantially so, than in the footpads or the ear (26). Chy mice, whether
on their original mixed-strain background or backcrossed 10
generations onto the C57BL/6 background, had profoundly
reduced RCT when they served as recipients of [3H]-cholesterol–
loaded macrophages injected into the rear footpad. Mean reductions in plasma at 24 hours were 77% and 74% for the 2 Chy
strains (Figure 2A), with a net reduction in RCT of 69% when we
compiled [3H]-cholesterol counts in the liver, plasma, and feces

(Figure 2B). By contrast, injection of [ 3H]-cholesterol macrophages in the body trunk skin where there were residual, though
still reduced, lymphatic vessels led to only a mean 25% inhibition
of RCT (Figure 2C), indicating that the impaired RCT correlated
with the extent of lymphatic vessel loss of transport. Plasma lipoprotein profiles were similar (Figure 2D), but HDL was actually
increased in Chy mice on the C57BL/6 background relative to
their littermate controls (Figure 2D), making the impaired RCT
in these mice even more striking. Thus, these data using a genetic
model confirm the critical importance of lymphatic transport in
RCT. The overall greater reduction in RCT in Chy mice compared
with the surgical model may be due to substantial, but incomplete, blockade of lymphatic drainage in the surgical model (Figure 1A) relative to the genetic model.
Vascular leakiness does not obviate the importance of lymphatic vessels in
RCT. We next examined whether lymphatic vessels would still retain
an important role in RCT at sites where the blood vasculature was
leaky, potentially increasing direct transfer of HDL into the vasculature. To set up a tractable model with a leaky vasculature as a
defining feature, we took advantage of the fact that tumors have a
leaky vasculature. Lewis Lung Carcinoma (LLC) cells were allowed
to form tumors in the ear pinnae of Chy mice or their littermate
controls (Figure 3A). Extravasated Evans blue dye within the ear,

Figure 3
Impact of vascular leakage on RCT through lymphatic vessels. (A) LLC cells were injected into the ear pinnae of Chy and control littermates (mice
on a mixed background were used). Tumors grew for 3 weeks before [3H]-cholesterol–loaded macrophages were injected as shown. (B) Increased
vascular permeability was documented using Evans blue dye injected i.v. with extraction of ear tissue 30 minutes later to quantify dye recovery
using a spectrophotometer. (C) Analysis of tritium counts in the plasma 24 and 48 hours later. Tumor-bearing mice were housed by requirement
under biohazard containment that precluded the use of individual caging needed to collect feces. Each panel represents 2 experiments performed
with 5 replicates per experimental group. Data represent the mean ± SEM comparing indicated conditions (B) or Chy and control mice at each
time point (C). *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
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Figure 4
Lymphatic vessel distribution in the mouse aorta and aortic sinus.
(A) The descending aorta is seen through its autofluorescence in the
green channel. Vessels staining positively for podoplanin and LYVE-1
are seen on the adventitial side of the aorta, weaving in and out of
adjacent adipose tissue. These vessels lack smooth muscle actin
(SMA) coverage, though some nearby blood vessels are positive.
LYVE-1+ SMA– lymphatic vessels are absorptive lymphatic capillaries,
rather than lymphatic collecting vessels. (B and C) LYVE-1 staining in
the region of the aortic arch. Arrows point to a lymphatic capillary along
the lesser curvature; arrowheads point out lymphatic capillaries near
arteries that branch off the arch. (D) Cross-sectional analysis of the
aortic sinus in an Apoe–/– mouse reveals lymphatic vessels under the
areas where plaque typically develops. (E) Both WT littermates and
Chy mice develop lymphatic vessels in the aorta as depicted in these
cross sections of the aortic sinus.

measured 30 minutes after i.v. injection, confirmed enhanced vascular leakage in the tumor and surrounding tissue (Figure 3B).
[3H]-Cholesterol–loaded macrophages were injected adjacent
to the tumor, upstream with respect to lymphatic flow through
the tumor-bearing skin, as indicated in Figure 3A. A marked
reduction in RCT (54%) was observed in Chy mice (Figure 3C),
indicating that lymphatic vessels remain dominant conduits for
RCT, even in tissues characterized by a leaky vasculature.
RCT from atherosclerotic aortae is impaired by anti-VEGFR3 mAb
that attenuates lymphatic vessel growth. To assess the potential relevance of findings in skin to the mode of cholesterol transport
in the aortic wall, lymphatic vessels were first identified in the
adventitia and surrounding adipose tissue of the entire aorta of
WT mice and in Apoe–/– mice with atherosclerosis (Figure 4A).
These vessels were absorptive lymphatic capillaries, as opposed
to lymphatic collecting vessels that transport lymph but do
not absorb, since they stained for both LYVE-1 and podoplanin
(11, 27, 28). The identified lymphatic capillaries wove in and out
of the adjacent adipose tissue and were therefore difficult to keep
completely intact when dissecting the aorta. A lymphatic capillary in the adventitia of the lesser curvature proximal to the aortic
sinus was consistently observed (Figure 4, B and C, arrow). Lymphatic vessels around the arteries that branch off the aortic arch
were observed, but their locations appeared more inconsistent, as
in Figure 4, B and C (arrowheads), which shows 2 specimens with
4

lymphatic vessels around different branching arteries. Lymphatic
vessels were richly abundant beneath plaques in the aortic sinus
(Figure 4D), again surrounded by adipose tissue.
The surgical and genetic approaches used above are unsuitable for assessing whether lymphatic vessels mediate RCT from
experimental atherosclerotic plaques. First, it is not technically
feasible to surgically disconnect lymphatic vessels from the intact
aorta. Second, in the genetic model of Chy mice, lymphatic vessels
were not absent in the aortic sinus (Figure 4E) or the arterial tree
(data not shown), but were absent in the skin. Indeed, Chy mice
and other genetic models of lymphatic vessel loss appear to have
relatively normal lymphatic vessels at non-skin sites (25, 29). To
generate a tractable model for the study of RCT, we turned to a
surgical model in which the aortic arch is transplanted into the
abdominal cavity of a recipient mouse. When the recipient is WT
and, therefore, has low LDL, this model supports robust disease
regression (30–32). The appeal of the model in our case was that
the surgery itself disrupts lymphatic connections and thus could
be used to determine whether reestablishing lymphatic connections led to differences in RCT.
We have reported that lymphatic vessels are regenerated within
3 days or less in the adventitia of the surgical site, which drains
lymph to the iliac lymph nodes (32). To better control the timing of cholesterol efflux in this model, we surgically transplanted
aortic arches from Apoe–/– mice containing atherosclerotic plaques
into the abdominal aortae of Apoe–/– recipients, rather than in WT
recipients that will undergo spontaneous regression. In Apoe–/–
recipients, which do not spontaneously regress (31), we could synchronously induce cholesterol efflux, as a key step in regression
and a prerequisite for RCT, by administering an apoE expression
vector at a given time point (1, 33). Immediately after surgery,
one-half of the recipient mice were treated with neutralizing antiVEGFR3 mAb AFL4 (34, 35) to selectively inhibit reformation of
an intact draining lymphatic vasculature, or with isotype-matched
control mAb that would allow lymphatics to reform. Prior to
transplantation, donor aortae were loaded with stable isotope–
labeled (deuterium-labeled) cholesterol ([2H]6-cholesterol; D6-cholesterol) using D6-cholesterol–rich liposomes delivered i.v. Delivery of D6-cholesterol to mice i.v. led to its rapid accumulation
in multiple organs, including high levels in the spleen and liver
initially (Figure 5A). D6-cholesterol was found mostly as unesterified cholesterol in spleen and liver (Figure 5A), suggesting that it
either remained packaged in liposomes or was transiently incorporated into cell membranes. However, in the aorta, where D6-cho-
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Figure 5
Role of lymphatic vessels in RCT from aortae. (A) Kinetics of D6-cholesterol were analyzed in duplicate 1 or 14 days after liposomes containing D6-cholesterol were administered i.v. Solid lines correspond to the left-hand y-axis that plots ng of D6-cholesterol detected in aortae. Data
depicted by dotted lines correspond to the right-hand y-axis that plots the esterified/total D6-cholesterol ratio. (B) Schematic diagram of the aortic
transplant positioned in the abdominal aorta. Green box depicts the portion of tissue collected for mass spectrometric (MS) analysis; orange box
shows the portion of tissue collected for imaging lymphatic regrowth. (C) Images of 2 independent pairings of mice transplanted on the same
day, 1 treated with control mAb and the other with anti-VEGFR3 mAb; stained for LYVE-1 (white vessels). Stars depict location of the lumen of
the transplanted aortic arch where it connects with the original aorta. Arrowheads point to surgical sutures that demarcate the boundary between
the transplant (Tx) and the original aorta (OA). Upper images show a pairing from 2 different orientations and lower images show a side view of
a different surgical pair. Scale bars: 250 μm. (D) Ester/total D6-cholesterol achieved at baseline prior to transplantation and ratios recovered in 5
pairs of transplants 4 weeks after surgery, treated with apoE vector at 2 weeks and with control or anti-VEGFR3 throughout (E and F). Total (E)
and esterified (F) D6-cholesterol recovered in pairs treated with control or anti-VEGFR3 mAb. D and E depict data as the mean ± SD (n = 5–9
for each bar). *P ≤ 0.05.

lesterol levels remained stable for up to 2 weeks, D6-cholesterol
increasingly entered the cholesterol ester pool, indicating that it
was incorporating into foam cells (Figure 5A). In plasma, high levels of D6-cholesterol were observed as early as 10 minutes after
D6-cholesterol delivery. By 2 weeks, most of the D6-cholesterol
had cleared from the circulation and much of what remained was
found in the pool of esterified cholesterol (Figure 5A), which in
this case is most likely because cholesterol was esterified by plasma
lecithin:cholesterol acyltransferase (LCAT).
Two weeks after transplantation and treatment with antiVEGFR3 or control mAb, we injected Apoe–/– recipients with an
apoE-encoding adenoviral vector (36) to induce cholesterol efflux
from plaque macrophages while mAb treatment continued. Previ-

ous results suggest that within 2 weeks cholesterol esters would be
reduced within plaques as they undergo mobilization from macrophages (1). Therefore, 2 weeks after apoE vector treatment, we
harvested transplanted aortae and quantified D6-cholesterol by
mass spectrometry. The transplanted aortic segment was collected
for this analysis, with most of the transplanted segment used for
mass spectrometric analysis and only a margin of the transplant
and its connection to the original aorta was retained for imaging
(Figure 5B). Two transplants were carried out per day with 1 recipient in the pair receiving control mAb and the other receiving antiVEGFR3 mAb. Images of the transplant interface near the original
aorta, shown here for 2 of the transplant pairs, revealed vigorous
lymphatic growth associated with transplantation (Figure 5C).
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The new vessels were differently oriented than the preexisting
vessels (compare Figure 4A with Figure 5C). This difference likely
reflects altered blood flow associated with the transplant, as blood
flow would determine patterns of interstitial fluid flow through
the aortic wall, in turn influencing lymphangiogenesis patterning (37). Lymphatic regrowth after transplantation was inhibited, albeit not completely, with anti-VEGFR3 mAb (Figure 5C).
Anti-VEGFR3 mAb treatment did not lead to impaired lymphatic
transport when assessed in skin (Supplemental Figure 3), suggesting that its main action was on the redevelopment of lymphatics
rather than on the transport function of existing vessels. However,
it was not possible to inject lymph flow tracers into the aortic wall
to quantify lymph transport locally.
As for the fate of D6-cholesterol, a very high proportion of
D6-cholesterol was located in the ester pool prior to transplantation (baseline) (Figure 5D), indicating that it was largely confined
to foam cells or intact lipoproteins in the aortic wall, rather than
less relevant compartments such as the medial smooth muscle
wall where it would be found as free D6-cholesterol. Even with
partial inhibition of lymphatic regrowth, anti-VEGFR3 mAb
treatment led to a greater retention of D6-cholesterol in the
transplanted aortae compared with those treated with control
mAb (Figure 5E), especially within the ester pool of D6-cholesterol (Figure 5, D and F). Since Vegfr3 mRNA was not expressed in
plaque macrophages (Supplemental Figure 4 and Supplemental
Methods), these data indicate that VEGFR3-mediated reformation of lymphatic connections in the aorta mediates RCT.
Discussion
With only a handful of clinical or experimental observations, a
few physicians as far back as the early 1980s have discussed the
logic of considering that a connection between atherosclerosis and
decreased lymph transport of cholesterol deserves attention (38–40).
However, to date, the quantitative importance of lymphatic vessels in RCT has not been examined, aside from a compelling study
that estimated that the net flux of HDL-C through human lymph
is substantial (14). With respect to atherosclerosis, the process of
macrophage RCT is most relevant, and many details have emerged
as to how cholesterol is mobilized from macrophages (6). Removal
of cholesterol from tissues where macrophages reside for subsequent return to the plasma and then the liver en route to fecal
secretion seems to logically involve lymphatic vessels. Indeed,
lymphatic vessels have widespread importance in macromolecular
transport from peripheral tissues in general.
Here, we provide experimental evidence that lymphatic vessels
are critical during macrophage RCT to bring lipidated apoA-I or
HDL-C to the plasma. We started our analysis in skin and chose
to employ a model where we could surgically disrupt lymphatic
transport from the mouse tail. This procedure necessitated the
injection of cholesterol-loaded macrophages into the mouse tail,
a site distinct from the peritoneal cavity where this assay for macrophage RCT was originally developed (6). It became clear that
macrophage RCT from the tail site was far less efficient than RCT
from the peritoneum and that other body sites, like the footpad,
were intermediate. This finding illustrates that different tissue
environments vary in their ability to support RCT and raises
important considerations that have yet to be explored, including
whether RCT from atherosclerotic plaque is quantitatively more
similar in the mouse tail or in the peritoneum; whether the rather
low RCT in the tail is due to tight macrophage packing in the
6

tail (as occurs in atherosclerotic plaque) that might limit apoA-1
access to the cells compared with dispersion of macrophages in
the peritoneum; or whether apoA1 levels in interstitial fluid vary
between organs or body sites.
We were able to counter poor macrophage RCT from the tail
by using Apoa1 transgenic mice and went on to uncover a quantitatively important role for lymphatic vessels in RCT that could
not be attributed to altered cholesterol efflux from macrophages.
When tail lymphatic vessels were surgically separated, we observed
a reduction in RCT of 50%. This reduction in RCT compared similarly to the magnitude of inhibition observed from compound
inhibition of ABCA1 and ABCG1 (19), key transporters for the
donation of free cholesterol to apoA-I during macrophage cholesterol efflux. An even more dramatic inhibition of RCT was
observed in the Chy mouse strain, which bears 1 copy of mutant
VEGFR3 with attenuated signaling. This loss of only 1 functional
VEGFR3 receptor is sufficient to prevent lymphatic vessels from
developing in many skin sites (29), most notably the extremities
(26). However, at other body sites, lymphatic vessels are not attenuated unless both copies of VEGFR3 are lost, a condition that is
incompatible with survival during embryogenesis (41). Indeed,
even in some skin sites, Chy mice have residual lymphatic vessels
(26), allowing us to show that the magnitude of inhibited RCT
correlated with the extent to which lymphatic vessels were absent
from the skin surrounding the site where cholesterol-loaded macrophages were injected.
We next considered the role of lymphatic vessels in RCT in the
aortic wall. Technically, this issue is challenging and none of the
models used in skin were valuable in the atherosclerosis-affected
aorta. We reasoned that a previous surgical model used to study
plaque regression had features necessary to address the main
technical obstacles (confining the D6-cholesterol tracer to the
aortic wall and disrupting the lymphatics, a natural consequence
of the surgery). The lymphatic regrowth that occurred in the controls was impressive, and this robust response may contribute
to why the surgical model allows for what appears to be more
aggressive regression than other models (1, 42). Unfortunately, it
is not technically possible to quantify lymphatic transport from
the aorta to determine whether anti-VEGFR3 mAb also affected
lymph transport in the aortic wall, but transport was not affected
systemically. Indeed, it has been established in a variety of scenarios that anti-VEGFR3 blocks the growth of new lymphatic vessels
but does not affect existing lymphatic vessels (35, 43–46). Thus,
the partial inhibition of lymphatic regrowth that we observed in
the aortae of anti-VEGFR3 likely accounts for its effect on retaining cholesterol in the wall of the transplanted aortic segments
relative to the controls. As we took measures to ensure that the
D6-cholesterol was largely in the esterified pool at the time of
transplantation, the cholesterol we traced originated either in
macrophages or in intact lipoproteins, which are the two dominant pools of cholesterol ester directly relevant to our study.
Cholesterol-laden macrophages and trapped lipoproteins are far
more abundant in intimal plaques than in adventitia. Indeed,
past studies have measured cholesterol esters in the aorta as a
surrogate for atherosclerotic plaque (47, 48). Thus, our findings
support the concept that clearance of cholesterol by RCT from
the arterial intima relies on lymphatic vessels.
Except in the most advanced plaques, where lymphatic capillaries can invade the intima along with the vasa vasorum (49), this
lymphatic vessel–driven mode of RCT would likely require that
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HDL-C cross the media to gain access to the adventitia. The literature suggests that such movement may preferentially occur
through pressure-driven convection (50, 51) and that hydraulic conductivity across the media is increased in the context of
hypercholesterolemia (52). Future studies are needed to continue
to investigate the role of lymphatic vessels in atherosclerosis and
RCT. However, the present findings indicate that the notion of
lymphatic vessels as a conduit for cholesterol transport from atherosclerotic plaques is a viable concept and that lymphatic vessel
biology in the area of atherosclerosis needs increased attention.
In past studies, we found that lymphatic transport is decreased
by hypercholesterolemia in Apoe–/– mice (27), and studies in
humans revealed that the rate of lymphatic transport was inversely
proportional to cholesterol traversing the lymph (12). This
reduced transport that occurs in the presence of high cholesterol
may promote cholesterol accumulation in the artery wall, as well
as in tissues like skin that are affected in hypercholesterolemia.
Even during conditions that support disease regression, cholesterol removal from plaques is not as rapid as other steps in disease
reversal. In particular, we were surprised to find that monocyte
recruitment is greatly reduced at a time when cholesterol clearance
from plaques is just getting underway (1). While the observation
may suggest that removal of bulk cholesterol is only part of what
is needed to reverse the progression of atherosclerosis, we view the
sluggish removal of cholesterol from plaques as a risk for allowing retained cholesterol to readily return to a state that supports
plaque progression. We argue that a more desirable disease-protective state is one in which cholesterol is mobilized from the aortic
wall in concert with treatments that support lesion stabilization
or regression. Thus, our next step is to identify strategies to restore
the impaired lymphatic transport that results from hypercholesterolemia and to determine whether such strategies can serve to
enhance the mobilization of cholesterol out of plaques when disease-reversing regimens are concurrently applied.
Methods
Mice. WT and Apoa1 transgenic mice (both C57BL/6) were obtained from
the National Cancer Institute (Frederick, Maryland, USA) and The Jackson Laboratories (Bar Harbor, Maine, USA), respectively. Chy embryos
were purchased from the Medical Research Council (MRC, Harwell, United
Kingdom) on a mixed C3H/HeH and 101/H background. A colony was
established and backcrossed to the C57BL/6 background. Since 1 mutant
allele is sufficient to confer loss of skin lymphatics (25), all control mice
were littermates bearing no copies of the mutations. Macrophages lacking
Abca1 and Abcg1 were obtained from mice housed at Columbia University.
Experiments were approved by the animal oversight committees at Mount
Sinai School of Medicine or Washington University.
Separation of lymphatic vessels in the mouse tail. We utilized a surgical technique to separate the dermal lymphatics while leaving the primary blood
circulation intact along the tail core (20). Briefly, tails were incised circumferentially at 2 locations spaced 2 mm apart, with the proximal incision
1 cm from the base of the tail through the skin. Skin between the 2 incisions was removed sufficiently to separate the lymphatic vasculature.
Extreme caution was taken to avoid damaging the underlying vasculature.
As a sham control, the tip of the tail was clipped to create an acute-phase
reaction without lymphedema. Plasma lipoproteins were analyzed as
described (1). In some mice, Evans blue dye was injected immediately after
surgery to verify the block in lymph drainage. For RCT studies, macrophages were injected immediately after the surgical separation of lymphatics or sham, avoiding significant lymphedema during the 48-hour assay.

Cholesterol-loaded macrophages and efflux using BODIPY-cholesterol. Total
bone marrow was obtained from mice by flushing femurs and tibiae of
mice with RPMI-1640. L929-conditioned medium was used to generate
bone marrow–derived macrophages (BMDMs) over a 6-day culture period.
To induce foam cell formation and label the intracellular cholesterol
pool, BMDMs were loaded on the sixth day of culture for 24 or 48 hours
in the presence of 100 μg/ml acetylated LDL (acLDL) that was previously incubated for 30 minutes at 37°C with 5 μM BODIPY-cholesterol
(23) (dissolved in ethanol) or 2.5 μCi/ml [3H]-cholesterol (PerkinElmer),
respectively. After 24 or 48 hours, respectively, cells were removed from
the culture dish using nonenzymatic cell dissociation medium (Cellgro,
Corning), washed twice with RPMI-1640, and equilibrated in 0.2% BSA
for 4 hours before injection. When cholesterol efflux was assessed in vitro,
BODIPY-cholesterol–loaded macrophages were cultured for 20 hours in
5% mouse serum. Cholesterol efflux was assessed directly on a single-cell
level by fluorescence microscopy or flow cytometry. After implantation in
vivo, transferred macrophages were retrieved from the skin by digesting the
skin with Liberase TM (Roche Applied Science) and staining for CD45.1
with exclusion of dead cells using propidium iodide.
In vivo RCT assay. To assess in vivo RCT, a total of 2.0 × 106 [3H]-cholesterol–labeled BMDMs containing 7 × 105 cpm were injected per mouse.
Cells were injected either i.p. (500 μl) or intracutaneously (20 μl) into the
footpad, back skin, or tail skin as indicated in Figures 1–3. Then mice were
housed individually in clean cages to allow for the collection of fresh feces
24 and 48 hours later. As in previous work (18), blood was collected at 24
and 48 hours, and plasma volume was measured and used for liquid scintillation counting. Feces were collected at 24 and 48 hours, as indicated
in Figures 1–3. Feces and livers were also weighed and subjected to liquid
scintillation counting.
Lipoprotein analysis. Total cholesterol levels were determined using a Wako
kit (catalog no. 439-17501) according to the manufacturer’s protocol.
Lipoprotein cholesterol distributions were determined using plasma samples diluted 1:1 in cold PBS centrifuged at 10,000 g for 2 minutes at 4°C.
Approximately 15 mg of cholesterol was injected into an HPLC system with
online mixing of enzymatic reagent (Cholesterol Liquid Reagent Set, Pointe
Scientific) with effluent from the column. The HPLC system consisted of
a Superose 6 10/300 GL column (GE Healthcare); a LaChrom Elite HPLC
system (Hitachi High Technologies) consisting of an L-2200 Autosampler
with Peltier cooling, an L-2420 UV-Vis Detector, and two L-2100 SMASH
pumps — 1 for delivering 0.9% saline with 0.01% EDTA and 0.01% sodium
azide at 0.4 ml/min to the column, and the other for delivering cholesterol
reagent (or water) at 0.125 ml/min; a 5 m (length) × 0.5 mm (internal diameter) knitted reaction coil (KRC 5-50; Aura Industries) in a water jacket
(CJB-10; Aura Industries) at 37°C; an Isotemp circulating water bath (Fisher
Scientific); a PEEK Tee (Upchurch part no. P-712) at the junction of column
effluent and total cholesterol reagent; and a personal computer running
ChromPerfect Spirit Chromatography Data System software, version 5.5
(Justice Laboratory Software) for data acquisition and analysis.
Tumors and vascular leakage assay. LLC cells (1.0 × 106 or 5.0 × 105) were
injected into the skin of the ear and allowed to grow for 3 weeks. A total of
5.0 × 106 [3H]-cholesterol–labeled foam cells containing 1.2 × 106 cpm were
injected intradermally in a single injection of 10 μl in the tip of the ear near
the tumor. To assess vascular leakage, mice were anesthetized and 200 μl of 2%
Evans blue dye (Sigma-Aldrich) was injected into the orbital vein. Thirty minutes later, the mice were euthanized and their ears were removed, and the blue
dye was extracted from skin using N,N-dimethylformamide (Sigma-Aldrich)
for 24 hours at 56°C and measured with a spectrophotometer (630 nm).
Aortic transplant procedure. Liposomes were prepared using cholesterol-26,26,26,27,27,27-d6 (D6-cholesterol) obtained from Sigma-Aldrich and
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) obtained from
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Avanti Polar Lipids. Ten milligrams (0.0255 mmol) of D6-cholesterol and
200 mg (0.263 mmol) of POPC were dissolved in chloroform, mixed, dried
onto the bottom of 13 × 100 mm glass tubes, and dried under vacuum
overnight. The next day, 6 ml of sterile saline was added to the tubes, which
were incubated for 1 hour at 40°C. The tubes were vortexed on a mechanical agitator for approximately 2–3 hours. Liposomes were stored at room
temperature until ready for injection.
Nineteen to 21-week-old Apoe–/– donor mice, placed on a Western diet at
6 weeks of age (Harlan Teklad 88137), received a 250 μl bolus injection of a
suspension of liposomes containing D6-cholesterol. Following treatment,
these donors were housed for 2 weeks to allow esterification of D6-cholesterol in plaques. Then heterotopic aortic transplants of the aortic arch (53)
were carried out in similarly aged and Western diet–fed Apoe–/– recipients.
Two surgeries were conducted each day. Immediately after surgery, the 2
mice were given 1.2 mg of AFL4 anti-VEGFR3 mAb (LEAF Purified; BioLegend) or isotype-matched control mAb (rat IgG2a, LEAF Purified; Biolegend)
i.p., respectively, and 0.6 mg every other day for a total of 4 weeks. Two weeks
after surgery, pairs were treated with apoE-encoding adenoviral vector (SignaGen) (1, 33). Pairs were euthanized 2 weeks after vector treatment, and
the transplant tissue was harvested for mass spectrometry or imaging as
specified. Liver and plasma samples were also collected, but D6-cholesterol
levels were too low for detection at the time of collection in these tissues.
Cholesterol analysis by GC-MS. Sample preparation was conducted by
a modification of a previously reported procedure (54). Briefly, lipids
were extracted according to Bligh and Dyer (55) after adding 4 μg of
[3,4-13C2]-labeled cholesterol as the internal standard. Extracts were evaporated under a stream of argon, dissolved in 1 ml of chloroform/methanol
(1:1) and stored at –80°C until analyzed. To measure free cholesterol, a
50-μl aliquot of each extract was evaporated under argon, and the residue
was dissolved in toluene and analyzed using a Finnigan TSQ Quantum
XLS mass spectrometer interfaced to a Trace gas chromatograph. To measure the total cholesterol, another 50-μl aliquot was saponified at room
temperature for 2 hours with methanolic KOH, cooled, and then extracted
with hexane. The hexane was evaporated under argon, and the residue was
dissolved in toluene and analyzed.
Samples of 1 μl each were injected onto a 250 μm × 10 m DB-1 capillary
column (J&W Scientific, Agilent Technologies). Helium was the carrier
gas at a constant flow rate of 1.0 ml per minute. The SSL injector temperature was 280°C, the interface 260°C, and the source 260°C. An oven
temperature program was used: 150°C for 1 minute, increased at 25°C per
minute to 215°C, followed by a 50-minute hold, then increased at 35°C
per minute to 260°C, followed by a 3.8-minute hold. The thermo triple
quadrupole (TSQ) was operated with the electron impact source in the positive-ion mode with a potential of 42 eV. Data were acquired in the selective
ion-reaction mode monitoring the following decompositions for choles1. Potteaux S, et al. Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe–/– mice during disease regression. J Clin Invest. 2011;121(5):2025–2036.
2. Spann NJ, et al. Regulated accumulation of desmosterol integrates macrophage lipid metabolism and
inflammatory responses. Cell. 2012;151(1):138–152.
3. Duewell P, et al. NLRP3 inflammasomes are
required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464(7293):1357–1361.
4. Hermansson A, et al. Inhibition of T cell response
to native low-density lipoprotein reduces atherosclerosis. J Exp Med. 2010;207(5):1081–1093.
5. Small DM, Bond MG, Waugh D, Prack M, Sawyer
JK. Physicochemical and histological changes in
the arterial wall of nonhuman primates during
progression and regression of atherosclerosis. J Clin
Invest. 1984;73(6):1590–1605.
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terol: 386.3 m/z > 301.3 m/z, for [3,4-13C2]-cholesterol; 388 m/z > 301.3 m/z
and 392.3 m/z > 307.3 m/z for [26,26,26,27,27,27-d6]-cholesterol. The collision cell energy was 10 V and the gas pressure was 1.0 mTorr. Corrections
were made for the 13C natural abundance. Ester cholesterol is reported as
the difference between total cholesterol and free cholesterol.
Statistics. Data are expressed as the mean ± SEM or SD, as indicated.
Statistical differences were assessed using a 2-tailed Student’s t test (when
comparing 2 datasets) or ANOVA (3 or more datasets) with Prism software,
version 4.2 (GraphPad).
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